Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. Mechanisms of acquired resistance are...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lung Cancer (Auckl)
Hlavní autoři: Klempner, Samuel J, Mehta, Pareen, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723122/
https://ncbi.nlm.nih.gov/pubmed/29255376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S147129
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky